�ٺ���Ƶ

A novel method of combining advanced optical imaging with an artificial intelligence algorithm produces accurate, real-time intraoperative diagnosis of brain tumors, a new study finds.

, the study examined the diagnostic accuracy of brain tumor image classification through machine learning, compared with the accuracy of pathologist interpretation of conventional histologic images. The results for both methods were comparable: the artificial intelligence–based diagnosis was 94.6 percent accurate, compared with 93.9 percent for the pathologist-based interpretation.

The imaging technique, stimulated Raman histology (SRH), reveals tumor infiltration in human tissue by collecting scattered laser light, illuminating essential features not typically seen in standard histologic images.

The microscopic images are then processed and analyzed with artificial intelligence, and in under two and a half minutes, surgeons are able to see a predicted brain tumor diagnosis. Using the same technology, after the resection, they are able to accurately detect and remove otherwise undetectable tumor.

“As surgeons, we’re limited to acting on what we can see; this technology allows us to see what would otherwise be invisible, to improve speed and accuracy in the OR, and reduce the risk of misdiagnosis,” says senior author Daniel A. Orringer, MD, associate professor in the at �ٺ���Ƶ, who helped develop SRH and co-led the study with colleagues at the University of Michigan. “With this imaging technology, cancer operations are safer and more effective than ever before.”

How the Study Was Conducted

To build the artificial intelligence tool used in the study, researchers trained a deep convolutional neural network (CNN) with more than 2.5 million samples from 415 patients to classify tissue into 13 histologic categories that represent the most common brain tumors, including malignant glioma, lymphoma, metastatic tumors, and meningioma.

In order to validate the CNN, researchers enrolled 278 patients receiving brain tumor resection or epilepsy surgery at 3 university medical centers in the prospective clinical trial. Brain tumor specimens were biopsied from patients, split intraoperatively into sister specimens, and randomly assigned to the control or experimental arm.

Specimens routed through the control arm—the current standard practice—were transported to a pathology laboratory and went through specimen processing, slide preparation by technicians, and interpretation by pathologists, a process which takes 20 to 30 minutes. The experimental arm was performed intraoperatively, from image acquisition and processing to diagnostic prediction via CNN.

Notably, the diagnostic errors in the experimental group were unique from the errors in the control group, suggesting that a pathologist using the novel technique could achieve close to 100 percent accuracy. The system’s precise diagnostic capacity could also be beneficial to centers that lack access to expert neuropathologists.

“SRH will revolutionize the field of neuropathology by improving decision-making during surgery and providing expert-level assessment in the hospitals where trained neuropathologists are not available,” says Matija Snuderl, MD, associate professor in the at �ٺ���Ƶ and a co-author of the study.

The Brain and Spine Tumor Center Offers Cutting-Edge Treatment

Dr. Orringer joined �ٺ���Ƶ in August 2019, bringing with him the SRH technology he helped to develop. �ٺ���Ƶ’s Brain and Spine Tumor Center is the first to offer this technique, using Invenio’s NIO Laser Imaging System, in New York City.

The newest addition to the center’s comprehensive suite of neurosurgical imaging technologies, SRH works in concert with intraoperative MRI and fluorescence-guided surgery to provide high-resolution precision guidance for �ٺ���Ƶ’s world-class neurosurgeons.

“�ٺ���Ƶ’s Department of Neurosurgery has long been a leader in bringing the most advanced treatment options to our patients,” says John G. Golfinos, MD, the Joseph P. Ransohoff Professor of Neurology and chair of the Department of Neurosurgery. “With the addition of Dr. Orringer’s expertise and this game-changing technology, we’re now even better equipped to provide safe surgeries and quality outcomes for the most complex brain tumor cases.”

The implementation of this new system is the most recent of �ٺ���Ƶ’s efforts to integrate artificial intelligence in clinical practice to improve diagnostics of cancer. Researchers and clinicians at �ٺ���Ƶ’s Perlmutter Cancer Center have made recent strides in lung cancer, breast cancer, and brain tumor.

Media Inquiries

Annie Harris
Phone: 212-404-3588
annie.harris@nyulangone.org